DK3472314T3 - PREPARATION OF FACTOR XA DERIVATIVES - Google Patents

PREPARATION OF FACTOR XA DERIVATIVES Download PDF

Info

Publication number
DK3472314T3
DK3472314T3 DK17814267.5T DK17814267T DK3472314T3 DK 3472314 T3 DK3472314 T3 DK 3472314T3 DK 17814267 T DK17814267 T DK 17814267T DK 3472314 T3 DK3472314 T3 DK 3472314T3
Authority
DK
Denmark
Prior art keywords
derivatives
factor
preparation
Prior art date
Application number
DK17814267.5T
Other languages
Danish (da)
Inventor
Mark Karbarz
Pamela B Conley
Genmin Lu
Original Assignee
Alexion Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60663351&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3472314(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alexion Pharma Inc filed Critical Alexion Pharma Inc
Application granted granted Critical
Publication of DK3472314T3 publication Critical patent/DK3472314T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6432—Coagulation factor Xa (3.4.21.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK17814267.5T 2016-06-17 2017-06-19 PREPARATION OF FACTOR XA DERIVATIVES DK3472314T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662351841P 2016-06-17 2016-06-17
PCT/US2017/038169 WO2017219034A2 (en) 2016-06-17 2017-06-19 Preparation of factor xa derivatives

Publications (1)

Publication Number Publication Date
DK3472314T3 true DK3472314T3 (en) 2021-07-26

Family

ID=60663351

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17814267.5T DK3472314T3 (en) 2016-06-17 2017-06-19 PREPARATION OF FACTOR XA DERIVATIVES

Country Status (23)

Country Link
US (4) US10604748B2 (en)
EP (2) EP3926044A1 (en)
JP (3) JP6959268B2 (en)
KR (1) KR102373215B1 (en)
CN (3) CN110167575B (en)
AU (2) AU2017283720C1 (en)
BR (1) BR112018075964A2 (en)
CA (1) CA3027457A1 (en)
CL (2) CL2018003654A1 (en)
CO (1) CO2019000120A2 (en)
DK (1) DK3472314T3 (en)
EA (1) EA037815B1 (en)
ES (1) ES2875538T3 (en)
HU (1) HUE054597T2 (en)
IL (1) IL263591B2 (en)
MX (1) MX2018015873A (en)
PE (1) PE20190661A1 (en)
PH (1) PH12018502614A1 (en)
PL (1) PL3472314T3 (en)
PT (1) PT3472314T (en)
SG (1) SG11201810915QA (en)
SI (1) SI3472314T1 (en)
WO (1) WO2017219034A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8268783B2 (en) * 2007-09-28 2012-09-18 Portola Pharmaceuticals, Inc. Antidotes for factor Xa inhibitors and methods of using the same
SG10201705189XA (en) * 2013-01-24 2017-07-28 Portola Pharm Inc INHIBITION OF TISSUE FACTOR PATHWAY INHIBITOR WITH FACTOR Xa DERIVATIVES
SG11201810915QA (en) * 2016-06-17 2019-01-30 Portola Pharm Inc Preparation of factor xa derivatives
WO2019246094A1 (en) * 2018-06-19 2019-12-26 Portola Pharmaceuticals, Inc. Antidotes to factor xa inhibitors
KR102337683B1 (en) * 2018-09-21 2021-12-13 주식회사 녹십자 Highly efficient anti-TFPI antibody composition

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5189019A (en) * 1990-04-23 1993-02-23 Merck & Co., Inc. Antistasin derived anticoagulant protein
US5589571A (en) * 1994-10-28 1996-12-31 Cor Therapeutics, Inc. Process for production of inhibited forms of activated blood factors
JPH1066572A (en) * 1996-08-29 1998-03-10 Showa Sangyo Co Ltd Production of soybean trypsin inhibitor of high purity
DK1259485T3 (en) 2000-02-29 2006-04-10 Millennium Pharm Inc Benzamides and related inhibitors of factor Xa
NZ567992A (en) 2005-11-08 2011-05-27 Millennium Pharm Inc Pharmaceutical salts and polymorphs of N-(5-chloro-2-pyridinyl)-2-[[4-[(dimethylamino)iminomethyl]benzoyl]amino]-5-methoxy-benzamide, a factor Xa inhibitor
US8268783B2 (en) 2007-09-28 2012-09-18 Portola Pharmaceuticals, Inc. Antidotes for factor Xa inhibitors and methods of using the same
SG185263A1 (en) 2007-09-28 2012-11-29 Portola Pharm Inc Antidotes for factor xa inhibitors and methods of using the same
US8455439B2 (en) 2008-11-14 2013-06-04 Portola Pharmaceuticals, Inc. Antidotes for factor Xa inhibitors and methods of using the same in combination with blood coagulating agents
CN102625712B (en) * 2009-07-15 2017-07-25 博尔托拉制药公司 Unit dose formulations and its application method for the antidote of factor XA inhibitor
SG11201408028YA (en) * 2012-06-14 2015-01-29 Portola Pharm Inc METHOD FOR PURIFICATION OF RECOMBINANT FACTOR Xa DERIVATIVES
US20140346397A1 (en) * 2012-12-27 2014-11-27 Portola Pharmaceuticals, Inc. Compounds and methods for purification of serine proteases
SG10201705189XA (en) * 2013-01-24 2017-07-28 Portola Pharm Inc INHIBITION OF TISSUE FACTOR PATHWAY INHIBITOR WITH FACTOR Xa DERIVATIVES
KR101988705B1 (en) * 2013-09-24 2019-06-12 화이자 인코포레이티드 Compositions comprising heterogeneous populations of recombinant human clotting factor xa proteins
JP6742986B2 (en) * 2014-08-20 2020-08-19 ポートラ ファーマシューティカルズ， インコーポレイテッド Freeze-dried preparation of factor Xa antidote
SG11201810915QA (en) * 2016-06-17 2019-01-30 Portola Pharm Inc Preparation of factor xa derivatives

Also Published As

Publication number Publication date
JP2019528242A (en) 2019-10-10
WO2017219034A2 (en) 2017-12-21
AU2017283720A1 (en) 2019-01-03
CN118271391A (en) 2024-07-02
JP2023086970A (en) 2023-06-22
JP6959268B2 (en) 2021-11-02
JP2022000477A (en) 2022-01-04
CA3027457A1 (en) 2017-12-21
EP3926044A1 (en) 2021-12-22
US20170369862A1 (en) 2017-12-28
CL2018003654A1 (en) 2019-01-25
IL263591B2 (en) 2023-03-01
JP7273918B2 (en) 2023-05-15
EA201990052A1 (en) 2019-05-31
BR112018075964A2 (en) 2019-04-02
CL2020001733A1 (en) 2020-09-25
CN116425860A (en) 2023-07-14
US11845966B2 (en) 2023-12-19
US20200208131A1 (en) 2020-07-02
HUE054597T2 (en) 2021-09-28
US20240076642A1 (en) 2024-03-07
KR102373215B1 (en) 2022-03-10
EP3472314A2 (en) 2019-04-24
AU2017283720C1 (en) 2024-07-25
SG11201810915QA (en) 2019-01-30
AU2017283720B2 (en) 2022-11-17
CN110167575B (en) 2024-03-15
PE20190661A1 (en) 2019-05-08
CN110167575A (en) 2019-08-23
IL263591B (en) 2022-11-01
KR20190019134A (en) 2019-02-26
SI3472314T1 (en) 2021-11-30
IL263591A (en) 2019-02-03
EP3472314B1 (en) 2021-05-05
US10954504B2 (en) 2021-03-23
EP3472314A4 (en) 2020-01-22
US10604748B2 (en) 2020-03-31
AU2023200825A1 (en) 2023-03-16
PT3472314T (en) 2021-06-18
ES2875538T3 (en) 2021-11-10
CO2019000120A2 (en) 2019-03-29
US20210348149A1 (en) 2021-11-11
WO2017219034A3 (en) 2019-03-14
PL3472314T3 (en) 2021-11-22
PH12018502614A1 (en) 2019-09-30
MX2018015873A (en) 2019-08-12
EA037815B1 (en) 2021-05-25

Similar Documents

Publication Publication Date Title
DK3512850T3 (en) INHIBITORS OF THE MENIN-MLL INTERACTION
DK3468966T3 (en) INHIBITORS OF THE MENIN-MLL INTERACTION
DK3137169T3 (en) INHIBITORIES OF LYSIN-SPECIFIC DEMETHYLASE-1
DK3302565T3 (en) FIXED DOSAGE FORMS OF PALBOCICLIB
DK3201410T3 (en) IMPROVEMENTS OF BUILDING COVERINGS
DK3554240T3 (en) COMBINATIONS OF ACTIVE CONNECTIONS
DK3178817T3 (en) AMORPHIC FORM OF TETRACYCLIC CONNECTION
DK3509581T3 (en) FORMULATIONS OF (R)-2-AMINO-3-PHENYLPROPYLCARBAMATE
DK3457851T3 (en) DERIVATIVES OF SOBETIR ROOMS
DK3180331T3 (en) POLYMORPHS OF SELINEXOR
DK3448846T3 (en) SYNTHESIS OF INDAZOLES
DK2845905T3 (en) Preparation of oligosaccharides
DK3157508T3 (en) FIXED ORAL DOSAGE FORM OF LIPOPHILE COMPOUNDS
DK3798222T3 (en) Crystalline form of the free base of lorlatinib
DK3448849T3 (en) SYNTHESIS OF INDAZOLES
DK3472314T3 (en) PREPARATION OF FACTOR XA DERIVATIVES
DK3307267T3 (en) TREATMENT OF MULTIPLE SHELLOSIS
DK3220891T3 (en) SUBLINGUAL FORMULATION OF RILUZOL
DK3294532T3 (en) IMPROVEMENTS IN THE MANUFACTURE OF WINDOW COMPONENTS
DK3094322T3 (en) ADMINISTRATION OF TASIMELTEON IN FIXED MODE
DK3368044T3 (en) TREATMENT OF HEPATIC STEATOSE-RELATED OLIGO-OVULATION
DK3201323T3 (en) Modification of bacteriophage
DK3297619T3 (en) Therapeutic uses of L-4-chlorokynurenine
DK3418273T3 (en) Derivatives of flavaglines
DK3328395T3 (en) NEW USE OF DEXTRANSULPHATE